CN117377488A - 靶向dll3和pd-1的组合疗法的给药方案 - Google Patents

靶向dll3和pd-1的组合疗法的给药方案 Download PDF

Info

Publication number
CN117377488A
CN117377488A CN202280031401.6A CN202280031401A CN117377488A CN 117377488 A CN117377488 A CN 117377488A CN 202280031401 A CN202280031401 A CN 202280031401A CN 117377488 A CN117377488 A CN 117377488A
Authority
CN
China
Prior art keywords
ser
gly
val
leu
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280031401.6A
Other languages
English (en)
Chinese (zh)
Inventor
N·H·萨拉威
A·谢蒂
M·米诺卡
玛丽-安妮·杜姆亚特·斯米特
H·王
S·罗伊乔杜里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CN117377488A publication Critical patent/CN117377488A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280031401.6A 2021-05-10 2022-05-06 靶向dll3和pd-1的组合疗法的给药方案 Pending CN117377488A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163186569P 2021-05-10 2021-05-10
US63/186,569 2021-05-10
PCT/US2022/028135 WO2022240688A1 (en) 2021-05-10 2022-05-06 Dosing regimen for combination therapy targeting dll3 and pd-1

Publications (1)

Publication Number Publication Date
CN117377488A true CN117377488A (zh) 2024-01-09

Family

ID=84029376

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280031401.6A Pending CN117377488A (zh) 2021-05-10 2022-05-06 靶向dll3和pd-1的组合疗法的给药方案

Country Status (12)

Country Link
US (1) US20240317856A1 (https=)
EP (1) EP4337252A4 (https=)
JP (1) JP2024518947A (https=)
KR (1) KR20240006585A (https=)
CN (1) CN117377488A (https=)
AU (1) AU2022273509A1 (https=)
CA (1) CA3217141A1 (https=)
CL (1) CL2023003357A1 (https=)
IL (1) IL307646A (https=)
MX (1) MX2023013227A (https=)
TW (1) TW202309092A (https=)
WO (1) WO2022240688A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120168667A (zh) * 2025-03-18 2025-06-20 中国科学院近代物理研究所 一种多肽在制备dll3过度表达的肿瘤的特异性靶向分子探针中的应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
JP2025508786A (ja) * 2022-02-23 2025-04-10 アムジェン インコーポレイテッド Ｄｌｌ３を標的とする癌治療
EP4630458A2 (en) * 2022-12-08 2025-10-15 Amgen Inc. Methods for treating dll3-expressing cancer
TW202509075A (zh) * 2023-05-19 2025-03-01 德商百靈佳殷格翰國際股份有限公司 T細胞銜接蛋白治療癌症之用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI793062B (zh) * 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
CN108136015A (zh) * 2015-08-20 2018-06-08 艾伯维施特姆森特克斯有限责任公司 抗dll3抗体药物缀合物以及使用方法
CA3095920A1 (en) * 2018-04-10 2019-10-17 Amgen Inc. Chimeric receptors to dll3 and methods of use thereof
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120168667A (zh) * 2025-03-18 2025-06-20 中国科学院近代物理研究所 一种多肽在制备dll3过度表达的肿瘤的特异性靶向分子探针中的应用

Also Published As

Publication number Publication date
EP4337252A1 (en) 2024-03-20
MX2023013227A (es) 2024-01-29
TW202309092A (zh) 2023-03-01
CA3217141A1 (en) 2022-11-17
US20240317856A1 (en) 2024-09-26
JP2024518947A (ja) 2024-05-08
IL307646A (en) 2023-12-01
CL2023003357A1 (es) 2024-06-07
AU2022273509A1 (en) 2023-10-19
WO2022240688A1 (en) 2022-11-17
KR20240006585A (ko) 2024-01-15
EP4337252A4 (en) 2025-04-23

Similar Documents

Publication Publication Date Title
CN117377488A (zh) 靶向dll3和pd-1的组合疗法的给药方案
AU2020276242B2 (en) Combination of PD-1 inhibitors and LAG-3 inhibitors for enhanced efficacy in treating cancer
JP2023126946A (ja) 抗ｌａｇ－３抗体、ｐｄ－１経路阻害剤および免疫療法剤の組み合わせを含む組成物
CN106794246B (zh) 肿瘤抗原特异性抗体和tlr3刺激以增强检查点干扰癌症疗法的性能
TWI908743B (zh) 抗dll3藥劑之給藥方案
WO2018133842A1 (zh) 人程序性死亡受体pd-1的单克隆抗体及其片段
EP4055055B1 (en) Bispecific antibodies against ceacam5 and cd47
WO2020007368A1 (zh) 低adcc/cdc功能性单抗及其制备方法与应用
CN119095619A (zh) 抗cd19药剂的剂量方案及其用途
AU2025202735A1 (en) Compositions and methods for treating extensive stage small cell lung cancer (es-sclc)
JP2022526640A (ja) 血液悪性腫瘍の治療における二重特異性ｃｄ１２３×ｃｄ３ダイアボディの投薬レジメン
JP2023543978A (ja) がん患者を治療するためのｐｄ－１拮抗薬及びｌａｇ３拮抗薬及びレンバチニブ又はそれの薬学的に許容される塩の併用療法
CN120529917A (zh) 使用抗CTLA4抗体与Pembrolizumab组合治疗癌症的方法
WO2023208990A1 (en) Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist,
EA051285B1 (ru) Схема введения доз комбинированной терапии, нацеливающейся на dll3 и pd-1
CN112672759A (zh) 抗程序性死亡配体-1(pd-l1)抗体的抗肿瘤用途
EA051880B1 (ru) Схема введения доз для средств на основе антитела к dll3
TW202436339A (zh) 治療選自非小細胞肺癌或三陰性乳癌的癌症之用途
CN118785922A (zh) 靶向dll3的癌症治疗
WO2023242351A1 (en) Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3
CN116670173A (zh) 抗ceacam5和cd47的双特异性抗体
KR20230087451A (ko) 암 환자를 치료하기 위한 pd-1 길항제 및 vegfr-2에 대한 길항제의 조합 요법
HK40089230A (zh) 药物组合物及用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination